Sort   by:  
 Page size 
ProteomicsAnti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma
The PI3K pathway is a major driver of cancer progression. However, clinical resistance to PI3K inhibition is common. IBL-302 is a novel highly specific triple PIM, PI3K and mTOR inhibitor. Screening IBL-302 in over 700 cell lines representing 47 tumor types identified neuroblastoma as a strong candi...
ORGANISM(S): Homo sapiens (Human) 
2019-07-11 | PXD014234 | Pride
Neuroblastoma Pi3k Ibl-302 Cisplatin Multikinase inhibition Lc-ms/ms 
GenomicsIBL-302 PIM/PI3K/mTOR triple kinase inhibitor treatment of patient derived orthotopic xenograft neuroblastoma cells
IBL-302 PIM/PI3K/mTOR triple kinase inhibitor treatment of patient derived orthotopic xenograft neuroblastoma cells
PRJNA550081 | ENA
UnknownAnti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma.
Not available
S-EPMC6685085 | biostudies-literature
UnknownPreclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer.
Not available
S-EPMC7118022 | biostudies-literature
UnknownAnti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma
Not available
S-SCDT-EMM-2018-10058-T | biostudies-other
TranscriptomicsIBL-302 PIM/PI3K/mTOR triple kinase inhibitor treatment of patient derived orthotopic xenograft neuroblastoma cells
neuroblastoma cells derived from PDOX models were treated with the kinase inhibitor.
ORGANISM(S): Homo sapiens 
2019-06-22 | GSE133137 | GEO
UnknownMacrocyclization as a Source of Desired Polypharmacology. Discovery of Triple PI3K/mTOR/PIM Inhibitors.
Not available
S-EPMC8591745 | biostudies-literature
Sort   by:  
 Page size